CTAS vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 18, 2026
CTAS
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | CTAS | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 35.5872 | 23.0415 | MRNA |
| PEG Ratio | 3.0579 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 8.9% | 260.2% | MRNA |
| Earnings Growth | 15.6% | -85.1% | CTAS |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 63.5/100 | 52.3/100 | CTAS |
| Profit Margin | 17.8% | -143.6% | CTAS |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | BUY | HOLD | CTAS |